seragy holding GmbH, a Germany-based biotechnology company developing biomarkers for neurodegenerative diseases, has secured €12 million in financing backed by Commerzbank, Mittelständische Beteiligungsgesellschaft Niedersachsen (MBG), and the State of Lower Saxony.
The financing combines debt, equity capital, and public funding. The Hanover-based company plans to use the capital to advance its proprietary SeRAS platform, expand its laboratory and analytical capabilities, and grow its local team.
Founded in 2022 as Prosperodes GmbH, seragy is led by co-founders Dr. Christiane Ritter and Dr. Thorsten Lührs, alongside Arne Ungruh, who brings expertise in business development and finance.
The company develops quantitative biomarkers for proteopathies, a group of diseases involving abnormal protein aggregation. Its work focuses on conditions including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
seragy’s SeRAS platform, which stands for Seed Replication, Analysis and Subtyping, is designed to analyse pathological protein aggregates in patient samples. It combines seeding-based biochemistry, high-sensitivity optical measurements, automated data analysis, and software algorithms.
The technology incorporates the MetisOne Analyzer, which is designed to produce quantitative molecular fingerprints of protein aggregation. These measurements are intended to help researchers distinguish molecular disease subtypes, characterise aggregation patterns, and monitor biological changes relevant to therapeutic development.
The platform is being developed to support pharmaceutical and biotechnology companies across drug discovery, preclinical research, and clinical development. seragy operates through its wholly owned subsidiary, seragy analytics GmbH, which handles services and research projects for industry partners.
Separately, seragy has received research funding from The Michael J. Fox Foundation for Parkinson’s Research to support the development of a quantitative SeRAS-based assay for Parkinson’s disease.
The foundation included the company, then operating as Prosperodes, among five recipients of funding under its Seed Amplification Assay Innovation Program in 2025. The programme supports research into methods for measuring disease-associated protein aggregation rather than identifying its presence alone.
The new financing will support further development of the SeRAS technology and the expansion of seragy’s laboratory infrastructure as the company works with pharmaceutical and biotechnology partners on biomarker applications.
